Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5941 AL 5955

Alternative drug therapies for dementia

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2011 May;49(5):17-20. doi: 10.3928/02793695-20110407-03. Epub 2011 Apr 27.

Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial

Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG; ADAPT Research Team.

Int J Geriatr Psychiatry. 2012 Apr;27(4):364-74. doi: 10.1002/gps.2723. Epub 2011 May 10.

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, Lee JH; Expect Study Group.

Curr Med Res Opin. 2011 Jul;27(7):1375-83. doi: 10.1185/03007995.2011.582484. Epub 2011 May 12.

A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial

Vreugdenhil A, Cannell J, Davies A, Razay G.

Scand J Caring Sci. 2012 Mar;26(1):12-9. doi: 10.1111/j.1471-6712.2011.00895.x. Epub 2011 May 12.

Persons with mild or moderate Alzheimer's disease learn to use urine alarms and prompts to avoid large urinary accidents

Lancioni GE, Singh NN, O'Reilly MF, Sigafoos J, Bosco A, Zonno N, Badagliacca F.

Res Dev Disabil. 2011 Sep-Oct;32(5):1998-2004. doi: 10.1016/j.ridd.2011.04.011. Epub 2011 May 14.

Reliability of peak treadmill exercise tests in mild Alzheimer disease

Anderson HS, Kluding PM, Gajewski BJ, Donnelly JE, Burns JM.

Int J Neurosci. 2011 Aug;121(8):450-6. doi: 10.3109/00207454.2011.574762. Epub 2011 May 17.

BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity

Evin G, Lessene G, Wilkins S.

Recent Pat CNS Drug Discov. 2011 May 1;6(2):91-106. doi: 10.2174/157488911795933938.

Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies

Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M.

Curr Alzheimer Res. 2011 Aug;8(5):592-606. doi: 10.2174/156720511796391935.

Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab

Panza F, Frisardi V, Imbimbo BP, Seripa D, Paris F, Santamato A, D'Onofrio G, Logroscino G, Pilotto A, Solfrizzi V.

Curr Alzheimer Res. 2011 Dec;8(8):808-17. doi: 10.2174/156720511798192718.

Selenium and Alzheimer's disease: a systematic review

Loef M, Schrauzer GN, Walach H.

J Alzheimers Dis. 2011;26(1):81-104. doi: 10.3233/JAD-2011-110414.

A clinical perspective: anti tau's treatment in Alzheimer's disease

Fuentes P, Catalan J.

Curr Alzheimer Res. 2011 Sep;8(6):686-8. doi: 10.2174/156720511796717221.

Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies

Navarrete LP, Pérez P, Morales I, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):678-85. doi: 10.2174/156720511796717122.

Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies

Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R.

Curr Alzheimer Res. 2011 Sep;8(6):659-65. doi: 10.2174/156720511796717177.

Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers

Calon F.

Curr Alzheimer Res. 2011 Aug;8(5):470-8. doi: 10.2174/156720511796391881.

Nutritional approaches to modulate oxidative stress in Alzheimer's disease

Pocernich CB, Lange ML, Sultana R, Butterfield DA.

Curr Alzheimer Res. 2011 Aug;8(5):452-69. doi: 10.2174/156720511796391908.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias